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AbstRACt
The prevalence of asthma has been rising in recent decades. It is the most common disease among pregnant women and 
affects ca. 12% of this population. The course of asthma in pregnancy may change. In 1/3 of patients, it worsens; in 1/3 of 
patients, the symptoms are milder; in 1/3 of patients, it remains unchanged. Well-controlled asthma decreases the risk of 
pregnancy complications. Uncontrolled and severe asthma increases the risk of congenital malformations and obstetrical 
complications for both mother and baby. Exacerbations may also contribute to poor pregnancy outcomes. These occur mostly 
either in the first or in the second trimester. The most common triggers are viral infections and treatment non-compliance. 
The key to maintaining and gaining control of asthma is active treatment of asthma and its exacerbations.
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IntRoduCtIon
The prevalence of allergic diseases and asthma has been 
rising in recent decades, reaching 5% of the adult, and 10% 
of the child and teenage population in Poland. Asthma is 
the most common disease complicating pregnancy, which 
affects 12% of pregnant women [1], and may lead to poor 
maternal and neonatal outcomes, especially in severe, un-
controlled, or inappropriately managed cases [2]. Likewise, 
pregnancy, by leading to multiple changes in the organism, 
influences the course of asthma. It is believed that the course 
of asthma during pregnancy improves in approximately 
one third of patients, in one third the course of the disease 
remains stable, and in one third it worsens. Worsening usu-
ally affects patients with uncontrolled and severe asthma, 
however it can also occur in patients with well-controlled 
symptoms [3]. Pregnant women with asthma need multi-
disciplinary and careful management.
The aim of this study is to summarize current knowledge 
on the bilateral relationship between asthma and preg-
nancy, and to sum up any recommendations concerning 
the management of asthma in pregnancy, as this remains 
a challenge in many aspects.
the possible influence of physiological 
pregnancy changes on the course of asthma
Developing pregnancy triggers many adaptive changes 
in the organism. Changes in the anatomical, hormonal, and 
immune system are particularly important for the control 
of asthma.
Anatomical changes in physiological pregnancy include: 
edema, increased vascularity in the upper respiratory tract, 
mucosa, and bronchodilation. The diaphragm is displaced, 
leading to changes in breathing, from a respiratory to ab-
dominal pattern. Tidal volume (TV) and inspiratory capacity 
(IC) increase, while functional residual capacity (FCR), total 
lung capacity (TLC) and vital capacity (VC) decrease during 
the course of pregnancy. Forced expiratory volume in one 
second (FEV1), peak expiratory flow (PEF) and airway resist-
ance remain unchanged [4, 5].
Other changes in the respiratory tract include an in-
crease in the respiratory rate and oxygen consumption (for 
approximately 20%). Eventually, PaO2 (partial pressure 
of oxygen) increases to the values 100–105 mm Hg, 
PCO2 (partial pressure of carbon dioxide) decreases to the 
values 27–32 mm Hg. The resulting alkalosis leads to renal 
loss of bicarbonates and to a decrease of bicarbonates blood 
concentrations to the values between 18–21mEq/L (Tab. 1). 
Even a small rise in pCO2 concentrations (above 35 mm Hg) 
may indicate respiratory failure and may lead to fetal acido-
sis. A decrease in PaO2 concentration below 70 mm Hg, indicates 
maternal hypoxemia and may also lead to fetal hypoxemia [4, 5].
Pregnancy leads to intensive hormonal changes. The 
blood concentration of many hormones rises. A two-fold 
change is observed in cortisol, a nine-fold change in pro-
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gesterone, and a 100–1,000 fold in estrogenes serum con-
centration. The increase in cortisol and progesterone should 
potentially lead to bronchodilatation; however, due to the 
competitive affinity of the above-mentioned hormones to 
the glucocorticoids receptor, the effect may be limited [5, 6].
Immunological changes in lymphocyte proportions dur-
ing pregnancy, described as Th2 domination, may predis-
pose to asthma exacerbations [5, 7]. Moreover, to prevent 
a maternal response to fetal antigens, the concentration of 
Th regulatory cells increases. This state results in decreased 
activation of effector lymphocytes T and natural killers (NK), 
which, in turn, leads to immunosuppression [7]. This increases 
susceptibility to viral infections and elevates the risk of pos-
sible complications if infection occurs [6]. One of the studies 
confirmed that the co-existence of asthma and pregnancy 
may predispose respiratory and urinary tract infections [8].
the influence of asthma on the course of 
pregnancy
Correspondingly, asthma may influence the course of 
pregnancy in numerous ways.
An association between asthma and gestational diabetes, 
perinatal hemorrhage, placental defects [2], pre-eclampsia [9], 
and congenital defects including cleft palate and gastroschisis [10], 
have been confirmed in several meta-analyses. Some studies 
indicated a risk of cesarean section [2], preterm birth [11], 
low birth weight, longer hospitalization of the newborn and 
even newborn death [12]. Possible mechanism of mentioned 
complications include hypoxia, maternal inflammation, 
changed uterine smooth muscle relaxation, reduction of 
placental 11 beta hydroxysteroid dehydrogenase enzyme 
and drug (mainly betamimetics) influence [10, 11], and is 
mostly linked with exacerbations [11]. Many authors and 
guidelines suggest that the complications may be prevented 
if appropriate effective treatment is used [11, 13]. The latter 
was confirmed in research from recent years, in which women 
with diagnosed asthma were enrolled in the programme be-
fore 18 week of gestation and obtained active management. 
This consisted of monthly visits with objective assessment, in-
cluding spirometry, fractional exhaled nitric oxide (FENO) and 
the adjustment of medication. A reduction in the prevalence 
of uncontrolled asthma of 80% was observed. Achieving good 
asthma control prevented most of the previously mentioned 
complications. However, the study confirmed that a small, 
but significantly higher, risk of pre-eclampsia and small for 
gestational age (SGA) is associated with asthma, despite good 
control [3]. The risk of SGA increases with increased asthma 
severity.
diagnostic tests in pregnancy
Proper diagnosis and evaluation of asthma control is 
crucial, particularly during pregnancy. General approach to 
asthma diagnose in pregnancy is the same as in non-preg-
nant patients. Tests generating a risk of pregnancy complica-
tions (provocation tests and skin prick tests) are contraindi-
cated during the whole course of pregnancy [4]. Acceptable 
tests are shown in a Table 2. Lung function tests are consid-
ered to be safe during pregnancy. Interpretation may be dif-
ficult, especially during the third trimester of pregnancy [14], 
due to associated physiological changes. One recent 
study demonstrated moderate changes in the pulmonary 
function. FEV1 declined significantly in second semester 
(mean 139 mL), then improved significantly in the last 
weeks of gestation (mean 51 mL higher to baseline). FVC 
and FEV6 changed insignificantly. Authors suggest that 
FEV6 may be used in asthma monitoring during pregnancy 
as it correlated positively with FVC. Nevertheless, changes in 
pulmonary function were not significantly associated with 
changes in asthma control [15]. PEF remains a valuable test 
during pregnancy. It should range between 380–550 L/min, 
but each asthmatic individual needs to establish his or 
her best effort. Maintaining levels > 90% of personal best 
value is considered optimal control [4]. Contraindications 
table 1. Reference ranges for arterial blood gases in pregnancy [5]
Investigations Pregnant
pH 7.40–7.45
pCO2² mmHg 27–32
pO2¹ mmHg 100–105 
Base excess No change
Bicarbonate (mmol/l) 18–21
Saturation 95–98%
¹ Pa O2 partial pressure of oxygen; ² PaCO2 partial pressure of carbon dioxide
table 2. Diagnostic tools in pregnancy 
diagnostic tools 
in pregnancy Remarks Contradictions
PEF useful/no changes, normal values described in the text
pre-eclampsia,
cervix 
insufficiency
spirometry
useful, problematic 
evaluation in advanced 
pregnancy,
pre-eclampsia,
cervix 
insufficiency
FEno useful no contraindications
blood gases changes in normal values no contraindications
oximetry changes in normal values no contraindications
Provocation 
tests –
generally 
contraindicated
sPt, ICt – generally contraindicated
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ered safe. Principals are adequate to those concerning 
non-pregnant patients (Tab. 3, Tab. 4). The authors agree 
that the treatment must be intensified if asthma control 
is insufficient, as complications of undertreated asthma 
markedly exceed the possible, but not fully proven, side 
effects of the treatment (Tab. 5). The basis of treatment 
are inhaled glucocorticoids (ICS). Other drugs including 
ipratropium, leukotriene receptor antagonists (LTRA), 
short and long acting betamimetics (SABA, LABA), sys-
temic glucocorticosteroids and omalizumab are also 
accepted in treatment, particularly in partly and uncon-
trolled asthma. Theophylline is not recommended to be 
used in pregnancy due to possible side effects. There is no 
table 3. Main points for good asthma management in pregnancy 
on the basis of a GINA report [13]
•	 Active asthma treatment outweighs the potential risk of 
medication use (evidence A)
•	 Use of available medication to achieve good symptom control 
and prevent exacerbation is justified, even if the safety is not 
completely proven (evidence A)
•	 Cessation of ICS is a risk factor for exacerbations (evidence A)
•	 Reduction of treatment is not recommended (evidence d)
•	 Educational resources for patients
•	 Monthly monitoring is recommended
•	 Monitoring and proper management of respiratory infections
•	 Early treatment of exacerbations with SABA, oxygen and systemic 
GCS is recommended
ICS — inhaled glucocorticosteroids; GCS — glucocorticoseroids;  
SABA — short acting betamimetics
table 4. Treatment of asthma in pregnancy [1, 13]
Step 1 ICs (small dose)*or none
Step 2
ICs (small dose)*
or LtRA*
or theophylline
Step 3
ICs (small dose) + LAbA*
or ICs (medium dose)*
or ICs (high dose)*
or ICs small dose + LtRA*
or ICS small dose + teophylline
Step 4
ICs (medium or high dose) + LAbA*
ICs high dose + LtRA*
ICS high dose + theophylline
add tiotropium
Step 5 
Higher lever care*
oral glucocorticost eroids*
add tiotropium
*Emboldened text suggests more suitable therapeutic option in pregnancy
for lung function testing include cervix insufficiency and 
pre-eclampsia [14].
Furthermore, the FENO test was found to be a useful 
diagnostic tool, and was proven to help in gaining asthma 
control, if used with monthly control [16]. Moreover, multi-
disciplinary management [14] and asthma control test were 
also proven to be useful during pregnancy. The latter test 
correlates well with actual asthma control. 
Asthma treatment in pregnancy, peripartum  
and lactation
Pregnancy
Despite constant concern about medication safety 
in pregnancy, asthma treatment is generally consid-
table 5. Treatment in pregnancy
treatment in pregnancy Former FdA class 
Possible side 
effects 
studies confirming 
occurrence of 
malformations 
Remarks
studies 
confirming 
safety of drugs 
betamimetics C
Cleft lip 
and palate, 
omphalocele
Garne [10]
Meta-analysis of Eltonsy 
indicates defects both in studies 
concluding on safety and those 
asserting side effects of the 
treatment [17]
Eltonsy [18]
Inhaled Glucocorticosteroids B/C
Musculoskeletal 
and heart defect 
for large doses
Blais [19] Defects confirmed only for large doses of inhaled GCS Garne [10]
systemic glucocorticosteroids C
Preterm birth, 
low birth weight, 
pre-eclampsia
Gregersen [20]
Mentioned findings should be 
balanced against severe asthma 
control
–
Antileukotriens B No connection – Short observation period Bakhireva [21]
Antimuscarinic agents B (ipratropium) – – – –
omalizumab B No connection – Short observation perriod Namazy [22]
Mepolizumab – – – – –
ISC — inhaled glucocorticosteroids; LABA — long acting betamimetics; LTRA — acting betamimetics
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sufficient data concerning tiotropium and mepolizumab 
in pregnancy.
Although guidelines on asthma treatment are easily 
accessible, most studies confirm a tendency to reduce treat-
ment in pregnant women.
Up to 40% of patients declared to give up treatment after 
getting pregnant without consultation with a doctor [6]. 
The declarations mentioned may be partly confirmed by 
a Dutch study using a large database, comprising of de-
tailed data on prescriptions. It shows a clear tendency for 
a reduction in the number of prescriptions issued after 
a diagnosis of pregnancy, which may indicate a decline in 
treatment after getting pregnant. This phenomenon may 
partly be the result of a milder course of asthma during 
pregnancy [23]. In addition, the problem of under-treatment 
is related to medical personnel, as pregnant asthmatics were 
significantly less likely to be given oral steroids, either in 
the emergency department or on discharge from hospital, 
than non-pregnant women [9], regardless of recommenda-
tions and results of studies that concluded on the relative 
safety of systemic GCS use for asthma exacerbations [12]. 
In the study cited, the use of systemic GCS was not related 
to poor perinatal outcomes, except for an increases rate of 
caesarean delivery.
Proper education on the treatment and safety of both 
patients and physicians may play an essential role in the 
improvement of asthma treatment during pregnancy.
Peripartum
Although exacerbations of asthma in peripartum period 
are rare, regular treatment should be maintained to avoid 
exacerbations. Hyperventilation [13] and drugs indicated 
due to obstetric and anesthetic management of labour may 
influence asthma and cause bronchospasm [24]. Short act-
ing betamimetics are drugs of choice for peripartum bron-
chospasm [4, 13]. Neonates require blood glucose control for 
the subsequent 48 hours after exposure to excessive doses 
of mentioned drugs, to detect possible hypoglycemia [13]. 
Specification and safety of the most frequently used drugs 
in peripartum period is enclosed in Table 6.
Breastfeeding
Although studies concerning safety of anti-asthmatic 
drugs are limited, most of the drug groups are considered 
safe in lactation. For inhaled glucocorticosteroids (budeson-
ide, fluticasone) infant exposure is far below the therapeutic 
level for an infant. Available in vitro studies for cicleson-
ide predict undetectable exposure of infant [25]. Inhaled 
betamimetics are accepted during breastfeeding as their 
concentrations in mothers’ blood remain low. [25, 26]. An-
tileukotrienes, anticholinergic agents and omalizumab are 
accepted if necessary for asthma control and the excretion 
into milk or bioavailability (omalizumab) is suggested to be 
minimal [27]. Among oral glucocorticosteroids prednisolone 
is preferred to avoid double peak of parent medicine and 
table 6. Drugs used in peripartum period [24]
Group of drugs drugs safe in asthma drugs contraindicated in asthma
Induction of labour In some cases drugs may be administered with caution eg. oxytocin generally contraindicated
Analgesia opioids administered with caution (risk of bronchoconstriction)
contraindicated in actively wheezing patient and in 
respiratory distress
Anestesia    
Epidural anesthesia opioids  
local anestetics avoid high and dense level of anesthesia due to possible impairment of accessory respiratory muscles
General anastesia only if regional anesthesia is contraindicated  
Intravenous ketamine  
propofol  
Volatile halogenated agents isoflurane  
sevoflurane  
Miorelaxants pancuronium atracurium
  cis-atracurium  
  rocuronium  
other treatment   betablockers
    ergot alkaloids 
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metabolite. The amount of drug excreted in milk remains 
low up to dose 80 mg [25].
Patophysiological factors influencing the course 
of asthma during pregnancy
Exacerbations
Exacerbations of asthma during pregnancy represent 
a significant problem that may lead to unfavourable preg-
nancy outcomes. About 5 to 20% of asthmatic pregnant 
women require medical intervention due to the occurrence 
of exacerbations of asthma during pregnancy [9]. It has 
been suggested that well-controlled asthma, together with 
no history of previous exacerbations and no prescribed 
controller medication, is associated with a lower risk of exac-
erbations during pregnancy [28]; however, these may occur 
in up to 37% of pregnancies complicated by well-controlled 
asthma, and 40% of these exacerbations may be severe [3].
In most of the studies, exacerbations occurred in the 
second trimester of pregnancy [9]. However, in one recent 
study, exacerbations were detected most frequently dur-
ing the first trimester of pregnancy [3]. Moreover, Blais et 
al. [29] confirmed the risk of congenital malformation and 
its association with exacerbations in 19% in of pregnancies 
during the first trimester. These findings may indicate a need 
for the intensification of treatment and management of 
asthma preconceptionally.
The most important trigger of exacerbations are infec-
tions, to which pregnant women are more susceptible due 
to adaptive changes in the immune system. Respiratory 
tract infections are the most frequent of these [8]. It was also 
confirmed that both pregnancy and asthma raise the risk of 
AH1N1 influenza [30]. Furthermore, influenza vaccination 
in pregnant asthmatics increased the improvement of the 
condition by 50%, in comparison with 15% in the patients 
who had not been vaccinated [31].
Another important factor for exacerbations is lack of 
treatment compliance [9]. Further factors include inade-
quate prenatal care, lack of or inappropriate GCS treatment, 
and smoking [6].
Some authors consider obesity and excessive weight 
gain in pregnancy a risk factor for the exacerbation of asth-
ma in pregnancy. Furthermore, an increased risk of gesta-
tional diabetes has been noticed in the group of patients 
with the co-morbidities of asthma and obesity [6].
The occurrence of severe exacerbations creates a risk 
of pre-term birth, small for gestational age [6] and pre-ec-
lampsia [3, 6].
Toxins and allergens exposure
Smoking, both active and passive, is an underestimated 
factor influencing the course of asthma during pregnancy. 
About 15% of pregnant women are active smokers [32]; 
another 30% are passively exposed to cigarette smoke [33]. 
Data from the United States shows that from 6 to 30% of 
pregnancies complicated with asthma are also complicated 
by active smoking [12]. Another study found more smok-
ers among the group of pregnant women with asthma 
than among pregnant women without asthma [6].
Smoking causes many well recognised pregnancy com-
plications [32] (Tab. 7); moreover, in pregnant women with 
asthma, it increases the risk of severe exacerbation and risk 
of urinary tract infection and pre-term birth [34].
A few studies examined the influence of atopy on the 
course of asthma in pregnancy. The research of Stenius-Aar-
niala, from 1988, found a more frequent occurrence of ex-
acerbations in non-atopic asthma.
Other factors
Some minor factors may also contribute to a worsening 
of asthma control during pregnancy or may additionally 
burden pregnancy.
The influence of psychological stress on the occurrence 
of exacerbations during pregnancies with asthma has been 
investigated in many studies. Some of them indicate that 
anxiety, and a perception by the patient of the asthma as 
being uncontrolled, may influence exacerbations and be 
a risk factor for a cesarean section. A more frequent occur-
rence of depression in pregnancies complicated by asthma 
exacerbations was confirmed by the Tata research, citated 
by Murphy [6].
However, some factors are found to be questionable.
No association was found between GERD and asth-
ma severity during pregnancy. A possible reason for this 
phenomenon may be related to an equal frequency in the 
presentation of GERD in pregnant and non-pregnant popu-
lations [35].
A few studies have suggested that fetal sex influences 
the course of asthma during pregnancy, with the course of 
asthma worsening with a female fetus. However, the data 
is inconsistent.
Education
Many guidelines point out the importance of education in 
asthma management and control [13]. This may be even more 
table 7. Side effect of smoking in pregnancy
•	 placenta previa
•	 abruptio placentae
•	 premature rupture of the membranes,
•	 pre-term birth
•	 intrauterine growth restriction 
•	 sudden infant death syndrome
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important during pregnancy, as up to 80% of female patients 
attempting to conceive are concerned about the influence of 
therapy on the fetus, and up to 40% cease treatment without 
consultation with a doctor. Pre-conceptional education, with 
an emphasis on treatment and symptoms of uncontrolled 
asthma, may play an important role in asthma management [6].
summary
Management of asthma during pregnancy remains 
a challenge in everyday practice. The essentials of good 
asthma management include proper education and active 
treatment of patients. Frequent and accurate monitoring is 
vital to prevent, detect and treat exacerbations, and other 
conditions influencing the course of asthma. Gaining and 
maintaining good asthma control may prevent adverse 
perinatal outcomes for both mother and baby.
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